These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34265496)

  • 1. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
    Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
    Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular Disease After Aromatase Inhibitor Use.
    Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
    JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
    Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
    Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
    Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
    Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
    Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
    Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
    Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: A systematic review and meta-analysis.
    Yu Q; Xu Y; Yu E; Zheng Z
    J Clin Pharm Ther; 2022 May; 47(5):575-587. PubMed ID: 34984740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
    Rabaglio M; Sun Z; Maibach R; Giobbie-Hurder A; Ejlertsen B; Harvey VJ; Neven P; Láng I; Bonnefoi H; Wardley A; Ruepp B; Castiglione M; Coates AS; Gelber RD; Goldhirsch A; Colleoni M; Thürlimann B; Regan MM
    Breast Cancer Res Treat; 2021 Feb; 185(3):697-707. PubMed ID: 33159633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
    Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
    Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiotoxicity of Use of Sequential Aromatase Inhibitors in Women With Breast Cancer.
    Khosrow-Khavar F; Bouganim N; Filion KB; Suissa S; Azoulay L
    Am J Epidemiol; 2020 Oct; 189(10):1086-1095. PubMed ID: 32338279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.
    van Ommen-Nijhof A; Jacobse JN; Steggink LC; Lefrandt JD; Gietema JA; van Leeuwen FE; Schaapveld M; Sonke GS
    Breast Cancer Res Treat; 2022 Dec; 196(3):591-602. PubMed ID: 36181605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
    Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
    Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
    Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
    Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
    Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
    J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
    Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
    Hamood R; Hamood H; Merhasin I; Keinan-Boker L
    Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
    Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.